Weight loss drugs grow even more effective

“By combining its weight-loss drug tirzepatide with eloralintide, a new drug that mimics a hormone involved in signaling fullness, Eli Lilly helped people with type 2 diabetes lose an average of 23.3 percent of their body weight over 48 weeks on the highest dose, compared with 14.8 percent for patients taking tirzepatide alone,” reports The Doomslayer.

The Wall Street Journal explains:

“A next-generation weight-loss drug from Eli Lilly red down pointing triangle, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study.

The experimental injection, eloralintide, which mimics a hormone called amylin that helps signal fullness after eating, was studied in combination with a Zepbound shot in patients with Type 2 diabetes.

Patients on the highest dose of the combination lost an average of 23.3% of their body weight over roughly 11 months while those on Zepbound alone lost an average of 14.8% of their weight. This data combines both the results from patients who stayed in the trial as well as the anticipated results of those that dropped out…

Citi’s Geoff Meacham said before the results that a weight loss of more than 18% would represent a ‘clean win’ for the company. The 23.3% weight loss was seen on the highest dose. On the middle doses, patients lost an average of roughly 20% and on the lowest doses, patients lost an average of 13.2%.”

Studies say that people who take the weight-loss drug Ozempic have better cancer outcomes.

A small clinical trial hints that Ozempic might slow aging. After taking the drug for eight months, participants scored three years ‘younger’ on biological age tests, with the biggest gains in brain and immune health,” reported The Doomslayer.

Ozempic may be helpful not just in fighting obesity and diabetes, but also in slowing the effects of Alzheimer’s disease.

Rapid weight loss has resulted in millions of people replacing their wardrobes. Airlines are expected to save a large amount of money on fuel once passengers slim down. Life insurers will likely save money and fewer will go broke, given the many causes of mortality associated with obesity.